Revance Therapeutics Inc (RVNC): Some bullet points from the AGN meeting:...

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	84
Posts	12534
Boards Moderated	0
Alias Born	07/25/2008

biotech_researcher

Re: None

Monday, 09/17/2018 1:28:59 PM

Monday, September 17, 2018 1:28:59 PM

Some bullet points from the AGN meeting:

• Update: The company expects to launch one or two new aesthetic products per year through 2025. BOTOX will still lead. Three new BOTOX indications will be pursued: treatment of the masseter muscle and platysma (broad sheet of muscle from the collarbones to the neck) prominence and skin quality in addition to pre-filled syringe configurations.
• Liquid formulation of a novel neurotoxin, nivobotulinumtoxinA, will be developed to treat frown lines and crow's feet.
• JUVEDERM indications will be expanded to include temple, tear trough, nose and fine lines in the upper face in addition to lower facial shaping.
• A hydrogel product, TE-HA, is being developed to the treatment of adults with acne scars.
• The new CoolSculpting platforms will be introduced over the next three years.